New Herpes Zoster Virus Research Has Been Reported by Researchers at Keio University School of Medicine [Optimal timing of recombinant herpes zoster virus vaccination for a JAK inhibitor treatment in rheumatoid arthritis: a multicentre,...].

Researchers at Keio University School of Medicine in Tokyo, Japan, have conducted a study on the optimal timing of recombinant herpes zoster virus vaccination for patients with rheumatoid arthritis who are undergoing JAK inhibitor treatment. The study aims to measure varicella zoster virus-specific IgG titers and T cell response in these patients. The research, funded by Pfizer Japan, involves a multicenter, open-label, randomized comparative study with 60 study subjects. The primary endpoint is to compare VZV-specific IgG antibody titers at week 12 with those at baseline in each group. The study has been approved by the Certified Review Board of Keio and follows ethical guidelines. [Extracted from the article]